Description
Triplixam (Perindopril Arginine, Indapamide, Amlodipine) Coated Tablets 5 mg/1.25 mg/5 mg. №30 Vial
Ingredients
- Active ingredients: Perindopril arginine, indapamide, amlodipine.
Dosage
- Recommended dosage: One tablet daily, or as directed by a healthcare professional.
Indications
- Indicated for: Treatment of hypertension in patients not adequately controlled with monotherapy.
Contraindications
- Contraindicated in: Patients with a history of angioedema related to previous ACE inhibitor therapy.
Directions
- Directions for use: Swallow the tablet whole with water, with or without food.
Scientific Evidence
Triplixam combines three antihypertensive agents with complementary mechanisms of action, resulting in enhanced efficacy compared to monotherapy. Perindopril inhibits ACE, amlodipine is a calcium channel blocker, and indapamide is a thiazide-like diuretic. This combination has shown superior blood pressure control in clinical trials.
- Perindopril has demonstrated effectiveness in reducing cardiovascular events in hypertensive patients.
- Amlodipine has been shown to reduce the risk of stroke and coronary artery disease.
- Indapamide, when combined with other antihypertensive agents, leads to significant reductions in blood pressure levels.
Additional Information
It is essential to monitor electrolytes and renal function regularly during treatment with Triplixam. Patients should be advised on the signs of hypotension and instructed to rise slowly from a sitting or lying position to minimize the risk of dizziness.
Triplixam has a favorable tolerability profile, with most adverse effects being mild and transient. Common side effects include dizziness, headache, and cough. In rare cases, severe allergic reactions may occur, requiring immediate medical attention.
